Rosa Laura E van Loon
Overview
Explore the profile of Rosa Laura E van Loon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Loon R, Bartelds B, Wagener F, Affara N, Mohaupt S, Wijnberg H, et al.
Front Pediatr
. 2015 Sep;
3:71.
PMID: 26380246
Background: Pulmonary arterial hypertension (PAH) is a pulmonary vascular disease with a high mortality, characterized by typical angio-proliferative lesions. Erythropoietin (EPO) attenuates pulmonary vascular remodeling in PAH. We postulated that...
2.
Knijnenburg J, van Bever Y, Hulsman L, van Kempen C, Bolman G, van Loon R, et al.
Eur J Hum Genet
. 2012 Mar;
20(9):986-9.
PMID: 22395867
Cat eye syndrome (CES) is caused by a gain of the proximal part of chromosome 22. Usually, a supernumerary marker chromosome is present, containing two extra copies of the chromosome...
3.
van Loon R, Roofthooft M, Hillege H, Ten Harkel A, van Osch-Gevers M, Delhaas T, et al.
Circulation
. 2011 Sep;
124(16):1755-64.
PMID: 21947294
Background: Incidence and prevalence rates for pediatric pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) are unknown. This study describes the nationwide epidemiological features of pediatric PH in the Netherlands...
4.
Bartelds B, van Loon R, Mohaupt S, Wijnberg H, Dickinson M, Boersma B, et al.
Chest
. 2011 Sep;
141(3):651-660.
PMID: 21940767
Background: Pulmonary arterial hypertension (PAH) is a progressive angioproliferative disease with high morbidity and mortality. Although the histopathology is well described, its pathogenesis is largely unknown. We previously identified the...
5.
van Loon R, Roofthooft M, Delhaas T, van Osch-Gevers M, Ten Harkel A, Strengers J, et al.
Am J Cardiol
. 2010 Jul;
106(1):117-24.
PMID: 20609658
Little is known about the effects of "second-generation drugs" (prostanoids, endothelin receptor antagonists, 5-phosphodiesterase inhibitors) in children with pulmonary arterial hypertension (PAH). This study describes the outcome of a national...
6.
van Loon R, Roofthooft M, van Osch-Gevers M, Delhaas T, Strengers J, Blom N, et al.
J Pediatr
. 2009 Jun;
155(2):176-82.e1.
PMID: 19524254
Objectives: To describe the clinical presentation of pediatric pulmonary arterial hypertension (PAH) and the intricacies of how to classify pediatric PAH according to the Venice classification. Study Design: Children (n...
7.
van Loon R, Hoendermis E, Duffels M, Vonk-Noordegraaf A, Mulder B, Hillege H, et al.
Am Heart J
. 2007 Sep;
154(4):776-82.
PMID: 17893008
Background: Data on long-term response to bosentan in adults and especially children with pulmonary arterial hypertension (PAH) associated with systemic-to-pulmonary shunt are scarce. Methods: We studied bosentan efficacy in 30...